Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

Cancer

Volumn 70, Issue 1 S, 1992, Pages 254-268

  Di Sant'Agnese, P Anthony ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

APUD; calcitonin; carcinoma; chromogranin; endocrine; neuroendocrine; paracrine; prostate; serotonin; small cell

Indexed keywords

CALCITONIN; CHROMOGRANIN; NEURON SPECIFIC ENOLASE; SEROTONIN; STREPTOZOCIN; TUMOR MARKER;

APUD CELL; CONFERENCE PAPER; ENDOCRINE FUNCTION; HUMAN; IMMUNOCYTOCHEMISTRY; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; SMALL CELL CARCINOMA; TUMOR DIFFERENTIATION;

APUD CELLS; CALCITONIN; CARCINOMA; CELL DIFFERENTIATION; CHROMOGRANINS; HUMAN; MALE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SEROTONIN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026642686     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E     Document Type: Article

References (160)

1. Prostate cancer
2. Carcinoma of the prostate
3. National Cancer Institute roundtable on prostate cancer: future research directions
4. Multidirectional differentiation in human epithelial cancers
5. Amphicrine cells, dysplasias, and neoplasias
6. Divergent differentiation in neoplasms: pathologic, biologic, and clinical considerations
7. Peptide‐hormone‐ and serotonin‐immunoreactive tumour cells in carcinoma of the prostate
8. APUD type endocrine tumor of the prostate: incidence and prognosis in association with adenocarcinoma
9. Neuroendocrine differentiation in prostatic carcinoma
10. Small cell carcinoma of the prostate: immunohistochemical and electron microscopic studies of 18 cases
11. Small cell carcinoma of the prostate: Part I. A clinicopathologic study of 20 cases
12. Neuroendocrine differentiation in prostatic carcinomas: a retrospective autopsy study
13. The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an “endocrine marker.”
14. Prostatic carcinoma: histological and immunohistological factors affecting prognosis
15. Neuroendocrine differentiation and prostatic carcinoma: the concept “comes of age” itorial
16. Neuroendocrine differentiation in prostatic carcinoma
17. Zur frage der endokrinie der menschlichen vorsteher‐druse
18. The cytochemistry and ultrastructure of polypeptide hormone‐producing cells of the APUD series and the embryologic, physiologic, and pathologic implications of the concept
19. Gut and pancreatic amine precursor uptake and decarboxylation cells are not neural crest derivatives
20. Uber das urogenitale helle‐zellen‐system des menschen
21. Sobre las celulas argentafines de la uretra y de la glandula prostatica
22. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium
23. Argentaffin and argyrophil cells in the prostate
24. The endocrine component of prostatic carcinomas, mixed adenocarcinoma‐carcinoid tumours and non‐tumour prostate: histochemical and ultrastructural identification of the endocrine cells
25. Endocrine cells in the prostate gland, urothelium and Brenner tumors: immunohistological and ultrastructural studies
26. Human prostatic endocrine‐paracrine (APUD) cells: distributional analysis with a comparison of serotonin and neuron‐specific enolase immunoreactivity and silver stains
27. Peptide‐hormone‐ and serotonin‐immunoreactive cells in normal and hyperplastic prostate glands
28. Endocrine‐paracrine cells of the prostate and prostatic urethra: an ultrastructural study
29. Calcitonin‐like immunoreactive and bombesin‐like immunoreactive endocrine‐paracrine cells of the human prostate
30. Calcitonin immunoreactive cells in prostate gland and cloacal derived tissues
31. Calcitonin, katacalcin and calcitonin gene‐related peptide in the human prostate: an immunocytochemical and immunoelectron microscopic study
32. Biology of disease: gastrin‐releasing peptide (mammalian bombesin) gene expression in health and disease
33. Somatostatin and/or somatostatin‐like immunoreactive endocrine‐paracrine cells in the human prostate gland
34. Glycoprotein hormone a‐chain‐immunoreactive endocrine cells in prostate and cloacal derived tissues
35. Partial characterization of a thyroid‐stimulating hormone‐like peptide in neuroendocrine cells of the human prostate gland
36. Determination of serotonin and 5–hydroxyindoleacetic acid in guinea pig and human prostate using HPLC
37. The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland
38. High concentration of immunoreactive calcitonin of prostatic origin in human semin
39. Calcium fractions in seminal plasma and functional properties of human spermatozoa
40. Immunoextracted calcitonin from human seminal plasma constitutes different forms
41. Bombesin‐like immunoreactivity in human seminal fluid
42. Isolation of a human seminal plasma peptide with bombesin‐like activity
43. Immunoreactive somatostatin in male reproductive system in humans
44. Parathyroid hormone: another pregnancy protein present in human seminal plasma and amniotic fluid
45. Seminal concentrations of total and ionized calcium from men with normal and decreased motility
46. On the possible existence of multiple endocrine, paracrine and neurocrine messengers in secretory cell systems
47. The endocrine cells of the digestive system: amines, peptides and modes of action
48. Local regulatory actions of gastrointestinal peptides
49. Neuroendocrine cells of the lung: an overview of morphologic characteristics and development
50. Gut endocrine and neural peptides
51. Morphological and immunohistochemical investigations of the utriculus prostaticus from the fetal period up to adulthood
52. Serotonin as a growth factor
53. Neuropeptides as growth factors: possible roles in human diseases
54. Serotonin and morphogenesis: Part I. Sites of serotonin uptake and ‐binding protein immunoreactivity in the midgestation mouse embryo
55. Adenocortical hyperplasia occurring with metastatic carcinoma of the prostate: report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion
56. Characterization by immunofluorescence of an ACTH‐like substance in nonpituitary tumors from patients with hyperadrenocorticism
57. Hyperadrenocorticism associated with “reactivated” prostatic carcinoma
58. Symptomatic hypokalemic alkalosis in hyperadrenocorticism secondary to carcinoma of the prostate
59. Inappropriate secretion of antidiuretic hormone by carcinoma of the prostate
60. Ectopic adrenocorticotro‐pin syndrome with prostatic carcinoma
61. Plasma‐immunoreactive‐calcitonin in patients with non‐thyroid tumours
62. Ectopic ACTH production in disseminated prostatic adenocarcinoma
63. Prostatic carcinoma producing syndrome of inappropriate secretion of antidiuretic hormone
64. Human chorionic gonadotropin in human neoplastic cells
65. Placental proteins and their subunits as tumor markers in prostatic carcinoma
66. Syndrome de secretion in appropriee de vaso‐pressine: A propos de trois observations
67. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia
68. Prostatic adenocarcinoma with ectopic ACTH production
69. Carcinoid tumor of the prostate associated with adenocarcinoma
70. Primary carcinoid of prostate
71. Primary carcinoid tumor of the prostate: report of a case
72. Ectopic production of human chorionic gonadotropin (hCG) by neoplasms: the value of measurements of immunoreactive hCG in the urine as a screening procedure
73. Diagnosis of carcinoid‐like metastatic prostatic carcinoma by an immunoperoxidase method
74. Relationship of ectopic ACTH production to tumor differentiation: a morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome
75. Diffuse carcinoid of prostate
76. Tumeur amphicrine de la prostate (adenocarcinome et carcinoide): incidences diagnostiques et therapeutiques
77. Carcinoid tumor of the prostate
78. Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney
79. Hypercalcemia in prostatic carcinoma: report of eight cases
80. Primary prostatic carcinoid tumor with intracytoplasmic prostatic acid phosphatase and prostate‐specific antigen
81. Ectopic secretion of corticotropin‐releasing factor as a cause of Cushing's syndrome
82. Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome: immunohistochemical study and review of the literature
83. Extrapulmonale klein‐zellige karzinome: eine raritat mit wichtigen therapeutischen konsequenzen
84. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross‐reacting antigen, beta‐chorionic gonadotrophin, and prostate‐specific antigen
85. The histogenesis of small cell carcinoma of the prostate: An immunohistochemical study
86. Argyrophilic prostatic carcinoma: case report with literature review on prostatic carcinoid and “carcinoid‐like” prostatic carcinoma
87. Endocrine‐paracrine cells in prostatic carcinoma and clinical course of the disease
88. Tumeur “carcinoide” de la prostate: une nouvelle observation anatomoclinique avec revue de la litterature
89. Small ‐cell carcinoma of prostate: transient complete remission with chemotherapy
90. Hypercalcemia in carcinoma of prostate: its cure by orchiectomy
91. Unique papillary cystadenocarcinoma of the prostate (in Russian)
92. Carcinoid tumour of the prostate associated with inappropriate ACTH secretion
93. Small cell carcinoma of the prostate [abstract]
94. Argyrophilic, “carcinoid‐like” prostatic carcinoma
95. Pure small‐cell carcinoma of the prostate with fatal liver metastasis
96. Cacitonin‐secreting carcinomas of the prostate: an immunohistochemical and ultrastructural analysis
97. Small cell carcinoma of the prostate gland with inappropriate antidiuretic hormone secretion: morphological, immunohistochemical and clinical expressions
98. Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment?
99. Prostatic carcinoma with endocrine features: a report of a neoplasm containing multiple immunoreactive hormonal substances
100. Production of beta‐human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract
101. Carcinoma of the prostate with Cushing's syndrome: a case report with histochemical and chemical demonstration of immunoreactive corticotropin‐releasing hormone in plasma and tumoral tissue
102. A case of small cell carcinoma of the prostate
103. Small cell carcinoma of prostate associated with myasthenic (Eaton‐Lambert) syndrome
104. Carcinome composite de la prostate asociant carcinome a petites cellules et adenocarcinome
105. Small cell carcinoma of prostate
106. Small‐cell carcinoma of prostate
107. Das endokrin differenzierte prostatakarzinom: histologic und immunohistochemie
108. Small cell carcinoma of the prostate
109. Production of calcitonin gene related peptide, calcitonin and PTH‐related protein by a prostatic adenocarcinoma
110. Investigation on serum neurone‐specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay
111. Elevated plasma chromogranin‐A concentrations in prostatic carcinoma
112. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic, and clinicopathological study
113. Prognostic value of neuro‐endocrine cells in prostatic adenocarcinoma [abstract]
114. Paraneoplastic syndromes associated with prostatic carcinoma
115. Carcinoid tumors: an analysis of 2837 cases
116. The prevalence and prognostic significance of argyrophil cells in colorectal carcinomas
117. Breast carcinomas with neuroendocrine differentiation
118. Hormonal therapy of prostatic carcinoma: is there a rationale for delayed treatment?
119. Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma
120. Rapid communication: immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas
121. Neuropeptides as cellular growth factors: role of multiple signalling pathways
122. Effects of bombesin on growth of human small cell lung carcinoma in vivo
123. Expression of the C‐terminal peptide of human pro‐bombesin in 361 lung endocrine rumours: a reliable marker and possible prognostic indicator for small cell carcinoma
124. Immunoreactive gastrin‐releasing peptide as a specific tumor marker in patients with small cell lung carcinoma
125. High affinity receptors for bombesin/GRP‐like peptides on human small cell lung cancer
126. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells (review)
127. Amine dependence of proliferative activity in two transplantable lines of mouse colonic carcinoma
128. Ectopic hormone production by a prostatic small cell carcinoma xenograft line
129. Bombesin stimulates growth of human prostatic cancer cells in vitro
130. Proliferation of endocrine (APUD‐type) cells during early N‐diethylnitrosamine‐induced lung carcinogenesis in hamsters
131. Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas
132. Age‐related changes in the neuroendocrine (endocrine‐paracrine) cell population and the serotonin content of the guinea pig prostate
133. Site‐specific growth of the prostate xenograft line UCRY‐PR‐2
134. Evaluation of serum neuron‐specific enolase as a tumor marker for carcinoma of the lung
135. Human pituitary tumors secrete chromogranin‐A
136. How sensitive and specific is measurement of plasma chromogranin A for the diagnosis of neuroendocrine neoplasia?
137. Calcitonin concentrations in lung cancer and non‐malignant pulmonary diseases
138. Use of serum tumor markers in cancer diagnosis and management
139. Subunit of the glycolytic enzyme enolase: nonspecific or neuron specific?
140. Immunoreactivities for chromogranin A and B, and secretogranin II in the guinea pig entero‐endocrine system: cellular distributions and intercellular heterogeneities
141. The granin (chromogranin/secretogranin) family
142. Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo
143. Bombesin‐like peptides can function as autocrine growth factors in human small‐cell lung cancer
144. Clinical use of a monoclonal antibody to bombesin‐like peptide in patients with lung cancer
145. The use of the long‐acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors
146. Treatment of the malignant carcinoid syndrome: evaluation of long‐acting somatostatin analogue
147. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth
148. Somatostatin analogs as adjuncts to agonists of luteinizing hormone‐releasing hormone in the treatment of experimental prostate cancer
149. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin
150. Receptors for prolactin, somatostatin, and luteinizing hormone‐releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone‐releasing hormone and somatostatin
151. Somatostatin inhibits VIP‐ and isoproterenol‐stimulated cyclic AMP accumulation in rat prostatic epithelial cells
152. Streprozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet‐cell carcinoma
153. Streptozocin plus fluoroouracil versus doxorubcin therapy for metastatic carcinoid tumor
154. The enterochromaffin cells in the mouse gastrointestinal tract after streptozotocin treatment
155. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms